Actively Recruiting Clinical Trials Studying Cancer Prevention Measures

Get Permission

This Clinical Trials Resource Guide lists actively recruiting clinical trials evaluating strategies to improve cancer prevention measures, mostly through increased rates of screening. Some of the following trials also address cancer prevention through improving knowledge of tumor biomarkers, patient health literacy, and other factors that may affect screening. This selection of trials focuses on the following tumor sites: breast, cervical, colorectal, gastric, and ovarian.

More information on these trials and other similar trials is available on the National Institutes of Health’s website at

Study Title: Participatory Research to Advance Colon Cancer Prevention

Study Type: Interventional/crossover assignment

Study Sponsor and Collaborators: Kaiser Permanente/Oregon Health and Science University/AltaMed Health Services

Purpose: To test strategies to increase the rate of colorectal cancer screening among the Latino population

Primary Outcome Measures: Increased colorectal cancer screening rates [time frame: up to 4 years]

Principal Investigator: Gloria Coronado, PhD, Kaiser Permanente; contact Jamie Thompson, MPH, at (503) 335-6335 or Identifier: NCT03167125


Study Title: Community-Based Cervical Cancer Prevention and Education Among Women Living With HIV

Study Type: Interventional/parallel assignment

Study Sponsor and Collaborators: Johns Hopkins University

Purpose: To test whether health literacy–focused interventions delivered by trained community health workers will be effective in promoting health literacy and increasing Pap test rates in women living with HIV

Primary Outcome Measures: Completion of Pap test [time frame: 6 months]

Principal Investigator: Hae-Ra Han, PhD, John Hopkins University School of Nursing; contact Dr. Han at (410) 614-2669 or Identifier: NCT03033888


Study Title: A Pilot Study of Hydroxytyrosol, a Component of Olive Oil, for Breast Cancer Prevention in Women at High Risk of Breast Cancer

Study Type: Interventional/single-group assignment

Study Sponsor and Collaborators: The Methodist Hospital System

Purpose: To evaluate the effect of hydroxytyrosol on mammographic density in women at high risk of developing breast cancer

Primary Outcome Measures: Breast density as assessed by mammography [time frame: 3 years]

Principal Investigator: Tejal Patel, MD, The Methodist Hospital System; contact the Houston Methodist Cancer Center at (713) 441-0629 or Identifier: NCT02068092


Study Title: Patient-Centered Cancer Prevention in Chinese Americans

Study Type: Interventional/parallel assignment

Study Sponsor and Collaborators: NYU Langone Health/National Institute on Minority Health and Health Disparities

Purpose: To assess the efficacy, adoption, and impact of an integrated intervention to improve adherence to recommended stomach cancer prevention guidelines for at-risk Chinese Americans in New York City

Primary Outcome Measures: Change in Helicobacter pylori eradication measured using breath ammonia measurement, fecal stool antigen test, or another clinically approved H pylori infection diagnostic test [time frame: at 2 months and at 6 months]

Principal Investigator: Simona Kwon, DrPH, MPH; contact Janet Pan at (212) 263-0483 or Identifier: NCT03340454


Study Title: Northwestern Ovarian Cancer Early Detection and Prevention Program: A Specimen and Data Study

Study Type: Observational/prospective

Study Sponsor and Collaborators: Northwestern University/National Cancer Institute

Purpose: To identify and develop highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecologic malignancies by collecting specimens and data

Primary Outcome Measures: Identification and development of highly sensitive and specific tumor markers for the detection and management of ovarian cancer and other gynecologic malignancies [time frame: outcomes will be assessed at the completion of the study]

Principal Investigator: Lee P. Shulman, MD, Robert H. Lurie Cancer Center; contact the Clinical Trials Office at the Robert H. Lurie Comprehensive Cancer at (312) 695-1301 or Identifier: NCT00005095 

Editor’s Note: The clinical trials presented here do not represent all the trials listed on For the complete list, go to